On the Role of Aggregates in the Immunogenicity of Recombinant Human Interferon Beta in Patients with Multiple Sclerosis
- 1 October 2010
- journal article
- review article
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 30 (10), 767-775
- https://doi.org/10.1089/jir.2010.0086
Abstract
Like many other therapeutic proteins, recombinant human interferon beta (rhIFN-β) elicits undesirable immune responses. rhIFN-β-treated multiple sclerosis patients may form binding antibodies and neutralizing antibodies (NAbs), with the latter being responsible for inhibition of the therapeutic effect of the protein. The incidence of binding antibodies and NAbs against rhIFN-β as well as the titer and persistence of NAbs differ among the marketed products. The proportion of patients forming antibodies against rhIFN-β-1b is higher than that against rhIFN-β-1a, which is likely explained by the differences in protein structure and aggregation behavior between the 2 types of rhIFN-β. Here, we summarize the different factors influencing the immunogenicity of rhIFN-β in patients with multiple sclerosis and discuss the role played by rhIFN-β aggregates.Keywords
This publication has 83 references indexed in Scilit:
- Monoclonal antibody interactions with micro- and nanoparticles: Adsorption, aggregation, and accelerated stress studiesJournal of Pharmaceutical Sciences, 2009
- Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product QualityJournal of Pharmaceutical Sciences, 2009
- Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple SclerosisArchives of Neurology, 2008
- N-Terminally PEGylated Human Interferon-β-1a with Improved Pharmacokinetic Properties and in Vivo Efficacy in a Melanoma Angiogenesis ModelBioconjugate Chemistry, 2005
- Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 yearsJournal of the Neurological Sciences, 2003
- Determinants of Autoantibody Induction by Conjugated Papillomavirus Virus-Like ParticlesThe Journal of Immunology, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinThe New England Journal of Medicine, 2002
- Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparationsImmunopharmacology, 2000
- NEUTRALIZING ANTIVIRAL B CELL RESPONSESAnnual Review of Immunology, 1997
- Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic MicePharmaceutical Research, 1997